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Abstract
Background: High quality care for acute myocardial infarction (AMI) improves patient outcomes. Still, AMI patients
are treated in hospitals with unequal access to percutaneous coronary intervention. The study compares changes
in treatment and 30-day and 3-year mortality of AMI patients hospitalized into tertiary and secondary care hospitals
in Estonia in 2001 and 2007.
Results: Final analysis included 423 cases in 2001 (210 from tertiary and 213 from secondary care hospitals) and
687 cases in 2007 (327 from tertiary and 360 from secondary care hospitals). The study sample in 2007 was older
and had twice more often diabetes mellitus. The patients in the tertiary care hospitals underwent reperfusion for
ST-elevation myocardial infarction, cardiac catheterization and revascularisation up to twice as often in 2007 as in
2001. In the secondary care, patient transfer for further invasive treatment into tertiary care hospitals increased (P <
0.001). Prescription rates of evidence-based medications for in-hospital and for outpatient use were higher in 2007
in both types of hospitals. However, better treatment did not improve significantly the short- and long-term
mortality within a hospital type in crude and baseline-adjusted analysis. Still, in 2007 a mortality gap between the
two hospital types was observed (P < 0.010).
Conclusions: AMI treatment improved in both types of hospitals, while the improvement was more pronounced
in tertiary care. Still, better treatment did not result in a significantly lower mortality. Higher age and cardiovascular
risk are posing a challenge for AMI treatment.
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Background
In the last decade, Estonia has reported one of the high-
est rates of mortality due to ischemic heart diseases in
Europe [1]. At the same time, as in other East European
countries, the health care system in Estonia has under-
gone considerable changes. Lead by the Estonian Society
of Cardiology, much effort has been made to improve
the quality of care for acute myocardial infarction (AMI)
patients through better application of the diagnosis and
treatment guidelines [2-7].
One of the main priorities has been to increase access
to percutaneous coronary interventions (PCI) and to
enable more ST-segment elevation AMI (STEMI)
patients receive reperfusion, including primary PCI.
According to a recent study, the rates of primary PCI in
Estonia are now comparable to those in such Nordic
countries as Norway and Denmark [8].
Previous studies have mainly focused on the overall
changes in the treatment and mortality of AMI patients
[9-14]. Changes in different types of hospitals with
unequal availability of coronary intervention facilities
have received little attention. Still, such information is
crucial in a country with limited health care resources
aiming to provide equal care for all AMI patients.
This study aimed to determine the changes in in-hos-
pital treatment and 30-day mortality and 3-year mortal-
ity of AMI patients hospitalized into tertiary and
secondary care hospitals in Estonia in 2001 and 2007.
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We conducted a retrospective cross-sectional study
based on patient records. The formation of the study
samples is presented in Figure 1. The list of AMI cases
(main diagnosis code I21-I22 according to the Interna-
tional Statistical Classification of Diseases and Related
Health Problems 10
th revision [15]) hospitalized from
January 1 to December 31, 2001 and 2007, was
obtained from the database of the Estonian Health
Insurance Fund (EHIF). The Estonian health insurance
system is a social insurance relying on the principle of
solidarity and of the 1.3 million inhabitants about 95%
are insured. Consistency in reporting to the EHIF
database and the validity of the data has been estab-
lished [16].
The EHIF applied the following exclusion criteria for
case selection: (1) patients who were not first hospita-
lized into one of the study hospitals; (2) patients who
were re-admitted with AMI within 28 days of the first
admission; (3) patients whose length of hospital stay was
less than 3 days if they were discharged alive and were
not transferred to another hospital, which made the
diagnosis of AMI unlikely.
In 2001, according to the EHIF database, 2365 AMI
cases were hospitalized during the study period in Esto-
nia. Management of AMI patients was shared among 27
Figure 1 Formation of the study samples in 2001 and 2007. AMI, acute myocardial infarction; EHIF, Estonian Health Insurance Fund.
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we aimed to evaluate the management of AMI patients
in hospitals that treat the major proportion of annual
AMI cases, the study included 9 hospitals: 2 tertiary
PCI-capable (only during working hours) and 7 second-
ary care hospitals. In the secondary care hospitals the
number of annual AMI cases ranged from 7 to 165
cases and the tending physicians were mainly anesthe-
siologists or internists and in some hospitals also cardi-
ologists. After the application of the exclusion criteria
by the EHIF, 1955 cases remained, out of which a ran-
dom sample of 520 cases (27%) was formed. The sam-
pling was performed in clusters according to the
hospitals involved.
In 2007, 3251 AMI cases were hospitalized in Estonia.
Due to the changes in the hospital network only 20 hos-
pitals admitted AMI patients in 2007. The study
included 16 hospitals that treated the major proportion
of annual AMI cases: 2 tertiary 24/7 PCI-capable and 14
secondary care hospitals (one hospital had PCI availabil-
ity during working hours). The tertiary care hospitals
w e r et h es a m ei nb o t ht i m ep e r i o d s .I nt h es e c o n d a r y
care hospitals the number of annual AMI cases ranged
from 16 to 267 cases and the tending physicians were
mainly anesthesiologists or internists and in some hospi-
tals also cardiologists. After the application of the exclu-
sion criteria by the EHIF, 2862 cases remained, out of
which a random sample of 800 cases (28%) was formed.
The sampling was performed in clusters according to
the hospitals involved.
Data collection
Data from medical records were retrospectively
abstracted by study experts according to a standardized
data collection form. Most of the experts were certified
cardiologists and all had received additional training on
data collection for this study. Every case was reviewed
by one expert. Data quality was monitored by random
re-abstractions for determining the causes of discrepan-
cies and followed by retraining of experts. The
abstracted data included: (1) patient baseline characteris-
tics; (2) time of symptom onset; (3) cardiac catheteriza-
tion, revascularization, and non-invasive cardiac testing
during index hospitalization; (4) in-hospital and dis-
charge medications; (5) in-hospital mortality. The date
of death during 3-year follow-up was obtained from the
Estonian Population Register by the EHIF. The study
was approved by the Research Ethics Committee of the
University of Tartu (reference number 196/T-1).
As we aimed to assess the quality of care of the first
hospital where the patient was hospitalized, the data col-
lection stopped when the patients were transferred from
a secondary care to a tertiary care hospital.
Statistical analysis
Categorical variables were expressed as frequencies and
percentages, and continuous variables as means and
standard deviations (SD), or as medians and interquar-
tile ranges (IQR). To compare the patients admitted
into the tertiary and secondary care hospitals in 2001
and 2007 in respect to baseline characteristics, in-hospi-
tal management and discharge prescription rates of
medications, the Chi-Square or the Fisher’se x a c tt e s t
for categorical variables and the t-test for two indepen-
dent samples or the Wilcoxon-Mann-Whitney test for
continuous variables were used.
The outcome was expressed as 30-day and 3-year
mortality. The crude and baseline-adjusted [age, sex,
AMI subtype (STEMI or non-STEMI), diabetes mellitus,
arterial hypertension, previous AMI, previous heart fail-
ure] hazard ratios (HR) of mortality for patients
admitted into the tertiary and secondary care hospitals
in 2001 vs 2007 were estimated with Cox’s proportional
hazards regression. The ratio with the 95% confidence
interval (CI) was presented as the ratio of the rate in
2007 to the rate in 2001 in the tertiary or secondary
care hospitals.
The experts found that the documentation of smoking
status and lipid profiles in medical records was incom-
p l e t ei n2 0 0 1a n d2 0 0 7( p e r c e n t a g eo fm i s s i n gv a l u e s
ranged from 14.5-48.8) and those variables were not
further analyzed in the patient characteristics of the
results section.
Two-sided P values ≤ 0.05 were considered statistically
significant. All analyses were performed using the Stata
statistical software version 11.
Results
Out of the random study samples (n = 520 in 2001, n =
800 in 2007), 40 (7.8%) cases in 2001 and 62 (7.8%)
cases in 2007 were excluded from the analysis because
of selection errors that arose in the forming of the study
population by the EHIF (the study sample included
cases that were not first hospitalized into one of the
study hospitals).
Among the remaining cases, the diagnosis of AMI
was confirmed for the following patients: 93.3% in
2001 and 95.3% in 2007 (P = 0.304) in the tertiary care
hospitals; 83.5% in 2001 and 91.1% in 2007 (P = 0.003)
in the secondary care hospitals. The diagnosis of AMI
in both study periods was based on the redefinition
document of myocardial infarction published in 2000
[2].
The final study samples included 423 cases in 2001
(210 from the tertiary and 213 from the secondary care
hospitals) and 687 cases in 2007 (327 from the tertiary
and 360 from the secondary care hospitals).
Blöndal et al. BMC Research Notes 2012, 5:71
http://www.biomedcentral.com/1756-0500/5/71
Page 3 of 8Patient characteristics
In the study sample of the tertiary care hospitals, the pro-
portion of men, patients with STEMI and diabetes melli-
tus was higher in 2007 compared to 2001 (Table 1). The
patients of the study sample in the secondary care hospi-
tals were considerably older, had more often diabetes
mellitus, and hypertension in 2007 compared to 2001.
Management during hospitalization
Prescription rates of evidence-based medications were
higher in 2007 in both types of hospitals (Table 2).
The patients of the tertiary care hospitals underwent
reperfusion for STEMI, cardiac catheterization and
revascularisation up to twice as often in 2007 as in
2001. The reperfusion rates for STEMI did not change
significantly in the secondary care hospitals.
Fourteen (6.6%) cases in 2001 and 74 (20.6%) cases in
2007 were transferred from a secondary to a tertiary
care hospital for further management (P < 0.001).
Medications for outpatient use
In order to analyze the prescription rates of medications
for outpatient use in the tertiary care hospitals, we
excluded the patients who died during hospital stay [30
(14.3%) in 2001 and 37 (11.3%) in 2007]. In the second-
a r yc a r eh o s p i t a l s ,w ee x c l u d e dt h o s ew h od i e dd u r i n g
hospital stay [36 (16.9%) in 2001 and 62 (17.2%) in
2007], or were transferred into tertiary care hospitals
[14 (6.6%) in 2001 and 74 (20.6%) in 2007].
The prescription rates of evidence-based medications
f o ro u t p a t i e n tu s ei n c r e a s e di na l ls t u d i e dd r u gg r o u p s
in both hospital types in 2007 compared to 2001 (except
for aspirin in the secondary care hospitals) (Table 3). At
the same time, there was a decrease in the use of
nitrates in both types of hospitals.
Mortality
In crude and baseline-adjusted analysis there were no
significant differences in the 30-day mortality and 3-year
mortality within the two hospital types in 2007 com-
pared to 2001 (Table 4 and Figure 2).
Comparison of mortality between the two hospital
types in 2001 showed no significant differences (results
not presented). However, in 2007, the 30-day mortality
was significantly lower in the tertiary care hospitals than
in the secondary care hospitals in crude (HR 0.54; 95%
CI 0.36-0.81) and baseline-adjusted analysis (HR 0.61;
95% CI 0.41-0.93). Also after 3 years mortality in the
tertiary care hospitals remained lower in crude (HR
0.66; 95% CI 0.51-0.85) and baseline-adjusted analysis
(HR 0.73; 95% CI 0.57-0.95).
Discussion
This country-wide study shows that between 2001 and
2007, the treatment of AMI patients improved in the
tertiary and secondary care hospitals in Estonia,
although the rates of reperfusion and revascularization
increased mainly in the tertiary care setting. At the
same time, improvements in the treatment did not
translate into significantly lower mortality within the
hospital types even after accounting of the differences in
the baseline characteristics. Instead, in 2007, a marked
mortality gap can be observed between the tertiary and
the secondary care hospitals.
The positive trend in AMI treatment during hospitali-
zation has also been reported by previous studies
Table 1 Baseline characteristics of patients hospitalized into tertiary and secondary care hospitals in Estonia in 2001
and 2007
Tertiary care hospitals Secondary care hospitals
Year 2001 Year 2007 P Year 2001 Year 2007 P
n = 210 n = 327 n = 213 n = 360
Mean age (SD), yrs 68.3 (12.7) 69.7 (12.0) 0.189 68.3 (12.4) 71.8 (11.4) 0.001
≥ 75 yrs, % 30.9 37.0 0.150 34.3 45.3 0.010
Men, % 66.7 58.1 0.047 52.1 51.9 0.969
STEMI, % 61.9 49.5 0.005 59.6 51.4 0.056
Diabetes mellitus, % 19.1 27.2 0.028 16.4 31.1 < 0.001
Arterial hypertension, % 70.0 70.0 0.914 57.3 75.8 < 0.001
Previous AMI, % 29.5 29.4 0.967 23.9 27.2 0.384
Previous heart failure, % 27.1 28.1 0.802 26.8 31.7 0.215
Time to presentation (hrs), %
≤ 3 50.0 42.5 0.215 33.3 30.8 0.878
3-12 24.3 24.8 25.8 25.3
> 12-24 9.5 9.8 12.2 12.2
> 24 16.2 22.9 28.6 31.7
AMI, acute myocardial infarction; SD, standard deviation; STEMI, ST-segment elevation myocardial infarction
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probably connected to better access to coronary inter-
vention facilities, the release of new European and Esto-
nian guidelines during the study period, and the
launching of several training programs by the Estonian
Society of Cardiology [3-7].
Still, in 2007, the mean use of beta-blockers and
ACEI/ARB during hospitalization and for outpatient use
remained below 83%, while the rates in the secondary
care hospitals were even lower. The use of statins in the
secondary care hospitals causes even more concern as
although the rates increased markedly during the study
period, their use is still below 38%. The fact that the
quality of care of AMI patients in the secondary care
hospitals lags behind that in their tertiary care counter-
parts may be due to the known slower implementation
of guideline-recommended medications in secondary
care hospitals [20]. As the study demonstrated, patients
in the secondary care hospitals tend to be older and
have more co-morbidities, which may influence manage-
ment decisions.
Better access to invasive coronary care facilities and
recent research findings contributed to the wider use of
PCI in the tertiary care hospitals. At the same time, in
the secondary care hospitals transfer for further cardiac
testing and revascularisation into tertiary care hospitals
Table 2 Management during hospitalization in tertiary and secondary care hospitals in Estonia in 2001 and 2007
Tertiary care hospitals Secondary care hospitals
Year 2001 Year 2007 P Year 2001 Year 2007 P
%% % %
n = 210 n = 327 n = 213 n = 360
Medications
Aspirin 87.1 94.2 0.004 88.3 86.4 0.428
Clopidogrel/ticlopidine 17.1 61.5 < 0.001 0.0 10.6 NA
Anticoagulants 89.0 93.0 0.092 85.4 92.8 0.007
Glycoprotein IIb/IIIa inh 12.4 38.8 < 0.001 0.5 3.1 0.037
Beta-blockers 79.5 82.6 0.395 76.1 77.8 0.707
Nitrates 92.4 78.9 < 0.001 96.7 85.6 < 0.001
ACEI/ARB 70.5 74.9 0.267 37.1 62.2 < 0.001
Statins 26.7 67.9 < 0.001 5.6 30.8 < 0.001
Cardiac catheterization 35.7 78.3 < 0.001 0.0 6.7 NA
Revascularisation 27.6 64.2 < 0.001 0.0 4.2 NA
PCI 22.4 61.5 < 0.001 0.0 4.2 NA
CABG 5.2 3.7 0.381 0.0 0.0 NA
Reperfusion for STEMI 42.3 64.2 < 0.001 44.1 34.1 0.073
Thrombolysis 35.4 7.4 < 0.001 44.1 34.1 0.073
Primary PCI 6.9 56.8 < 0.001 0.0 0.0 NA
Echocardiography 81.9 85.3 0.292 52.1 51.9 0.969
Stress-testing 19.0 1.8 < 0.001 8.0 2.6 0.023
ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; CABG, coronary artery bypass grafting; NA, not applicable; PCI,
percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction
Table 3 Medications prescribed for outpatient use in tertiary and secondary care hospitals in Estonia in 2001 and
2007
Tertiary care hospitals Secondary care hospitals
Medications Year 2001
%
Year 2007
%
P Year 2001
%
Year 2007
%
P
n = 180 n = 290 n = 163 n = 224
Aspirin 85.1 93.1 < 0.001 79.8 82.6 0.776
Clopidogrel/ticlopidine 18.3 65.2 < 0.001 0.6 10.3 < 0.001
Beta-blockers 71.3 80.0 0.035 68.7 80.8 0.032
ACEI/ARB 66.7 77.6 0.007 37.4 69.2 < 0.001
Statins 31.5 73.4 < 0.001 14.5 37.1 < 0.001
Nitrates 61.9 22.1 < 0.001 85.3 58.0 < 0.001
ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers
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previous studies [21,22]. Although the mean age of
transferred patients increased, transferred patients still
tended to be younger than the non-transferred patients
(data not presented).
While in the tertiary care hospitals reperfusion rates
increased and primary PCI became the preferred method
of reperfusion for STEMI patients, then in the secondary
care hospitals reperfusion rates showed little change. It is
possible that STEMI patients are usually transferred
before receiving medical reperfusion. Still, a previous
study revealed that the reasons for not receiving reperfu-
sion may be unknown in up to 45% of cases [23].
Several studies have demonstrated that closer adher-
ence to published guidelines for AMI management
results in improved short-and long-term outcomes and
this even despite the growing prevalence of risk factors
(older age, history of hyperlipidaemia and diabetes melli-
tus) at presentation [10-14,16,24-26]. Although our
study demonstrates a marked improvement in the treat-
ment quality for AMI patients in 2007 compared to
2001, especially in tertiary care hospitals, it fails to show
a significant decrease in 30-day and 3-year mortality. As
the study sample of the secondary care hospitals demon-
strated, this may largely be due to the higher age and
cardiovascular risk among the study samples in 2007.
For instance, the rates of diabetes had almost doubled
in both types of hospitals. In order to further clarify this
issue, we performed a sub-analysis to compare the base-
line characteristics, quality of care provided, and mortal-
ity separately among patients < 75 and ≥ 75 years in
2001 and 2007 in tertiary care hospitals (data not pre-
sented). On the basis of this analysis we may hypothe-
size that in tertiary care hospitals the reason why short-
and long-term mortality has not improved despite better
overall quality of care is that firstly the improvement is
more targeting those younger and healthier and sec-
ondly the rate of patients over 75 years with more co-
morbidities has increased.
Interesting findings of the study were the differences in
short and long-term mortality between the two hospital
types in 2007. This can probably be explained by a com-
bined effect of improved management possibilities in the
tertiary care hospitals and different patient baseline char-
acteristics in the two hospital types. The patients
admitted to the secondary care hospitals are more likely
to be older and have a higher cardiovascular risk. More-
over, as the elderly often present with atypical symptoms
and have a greater burden of cardiac and non-cardiac co-
morbidities, physicians are more reluctant to treat them
aggressively, the more so when the outcomes of interven-
tions and surgery may be poorer [27,28].
Limitations
Firstly, this study includes only random study samples
which may not represent the true patient populations.
As a consequence, the practice patterns observed in the
present study may not be representative of the general
AMI patient population. Secondly, the sample of 2007
included patients from seven secondary care hospitals
that were not included in 2001 (accounting for 25% of
the cases from the secondary care hospitals). This corre-
sponds to the study principle of including hospitals that
Table 4 Mortality of patients hospitalized into tertiary and secondary hospitals in Estonia in 2001 and 2007
Year 2001 Year 2007
Mortality % % P HR (95% CI) Adjusted HR (95% CI)
a
30-day
Tertiary care hospitals 17.6 13.2 0.156 0.71 (0.44-1.15) 0.69 (0.42-1.13)
Secondary care hospitals 20.2 22.5 0.516 1.17 (0.78-1.77) 1.01 (0.66-1.55)
3-year
Tertiary care 35.7 32.7 0.475 0.90 (0.66-1.22) 0.90 (0.65-1.23)
Secondary care hospitals 38.5 45.3 0.113 1.24 (0.94-1.64) 1.03 (0.77-1.37)
CI, confidence interval; HR, hazard ratio
a Adjusted for age, sex, AMI subtype (STEMI or non-STEMI), diabetes mellitus, arterial hypertension, previous acute myocardial infarction and previous chronic
heart failure.
Figure 2 Baseline-adjusted 3-year cumulative mortality hazards
of patients hospitalized into tertiary and secondary care
hospitals in Estonia in 2001 and 2007.
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ing the analysis to only those secondary care hospitals
that participated both in 2001 and 2007 produced simi-
lar treatment and mortality results (data not presented).
Thirdly, the study did not capture information on co-
morbid conditions such as chronic kidney disease and
cancer, which may have precluded the use of certain
pharmacologic and interventional treatments. Fourthly,
owing to the study design, we were not fully able to col-
lect information on smoking and lipid profiles and
hence we could not account for these variables in mor-
tality analysis.
Conclusions
In Estonia, both types of hospitals underwent consider-
able improvement in AMI treatment between 2001 and
2007. Still, changes were more pronounced in the ter-
tiary care setting, especially with respect to the use of
reperfusion and revascularisation. Low rates of reperfu-
sion and transfer for PCI clearly need to be addressed in
the secondary care hospitals. The improvement in treat-
ment did not result in a significant change in short-and
long-term mortality in either hospital type. Higher age
and cardiovascular risk are posing a challenge for AMI
management.
In addition to addressing the gaps in the quality of
AMI treatment across Estonian hospitals, there is a
need for high-quality data from a prospective nation-
wide acute myocardial infarction register for continuous
follow-up of AMI treatment and outcomes.
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